Introduction
Time-related structural valve deterioration (SVD) leading to regurgitation or stenosis is the major drawback of bioprosthetic valves. Leaflet tissue degeneration, with or without calcification, is the most common cause of bioprosthetic valve failure. Usually, the term SVD refers to changes intrinsic to the valve, such as wear, fracture, calcification, and leaflet disruption or leaflet retraction of a prosthetic valve. Typically, calcification involves the valve cusps and commissures with stiffening resulting in stenosis and regurgitation.
. implantation (TAVI) to improve symptoms and survival in symptomatic patients with severe aortic stenosis (AS) who cannot undergo surgical replacement or are at high risk for this intervention. 6 Currently, TAVI is a consolidated procedure in which a bioprosthetic valve is inserted through a catheter and implanted within the diseased native aortic valve. 7 A marked and durable improvement in functional class and quality of life after TAVI has been documented. 8 Few studies only reported data on SVD of the implanted valves at long-term follow-up. [9] [10] [11] [12] However, these data are crucial for assessing valve durability and consequently to better define indications for this procedure, before TAVI is used more widely in clinical practice. Thus, the aim of this study was to investigate with long-term echocardiography follow-up anatomical and functional changes of a balloonexpandable transcatheter valve prosthesis.
Methods

Study design
Our study population included consecutive patients with symptomatic severe AS undergoing TAVI at the Centro Cardiologico Monzino IRCCS in Milan, Italy between April 2008 and December 2011. Severe AS was defined as an aortic valve area (AVA) < _1 cm 2 (indexed 0.6 cm 2 /m 2 ), a peak velocity > _4 m/s, and a mean trans-aortic pressure gradient > _40 mmHg. All patients were considered at high operative risk or had contraindications for conventional surgical aortic valve replacement. A multidisciplinary heart team including a cardiologist, a cardiac surgeon, an interventional cardiologist, an imaging specialist and a cardiac anaesthesiologist determined eligibility for TAVI, access route and prosthesis size. All patients received either the 23-or 26-mm balloon-expandable Edwards SAPIEN or SAPIEN XT valves (Edwards Lifesciences, Inc., Irvine, CA). The device was delivered through either the transfemoral or the transapical approach. Before hospital discharge and at follow-up, all patients underwent clinical evaluation that included classification of heart failure symptoms according to the New York Heart Association (NYHA) functional class. Mortality rate for cardiac and non-cardiac causes was recorded. The institutional ethics committee approved the study and all study participants provided written informed consent.
Echocardiography
Comprehensive TTE (M-mode, 2D and Doppler) evaluation was performed using commercially available equipment (iE33, Philips Medical System, Andover, MA, or Vivid-7 or E9, GE Healthcare, Horten, Norway) prior to TAVI and within 5 days after the procedure (pre-discharge), at 1-year and at 5-year follow-up. Two dimensional TTE was performed in multiple cross-sectional and off-axis views with careful attention to assessing the morphology and mobility of prosthetic valve leaflets, evaluating the integrity of the cusps and detecting the presence of calcification. Using the biplane Simpson's method, left ventricular (LV) end-diastolic and end-systolic volumes and maximal left atrial (LA) volume were measured, and LV ejection fraction was derived. Doppler-derived parameters including peak velocity, mean pressure gradient and velocity-time integral of the jet by continuous-wave Doppler were assessed from the apical, right parasternal, right supraclavicular and suprasternal positions. Prosthesis AVA was derived from the continuity equation according to guidelines, with the LV outflow tract diameter measured in the mid-systole from the parasternal long-axis view in a zoomed mode, from inner-edge to inner-edge of the prosthetic valve. 13 The LV outflow tract velocity-time integral was obtained using pulsed-wave Doppler and positioning the sample volume 5 mm below the aortic leaflets.
All echocardiographic measurements were obtained by averaging the values collected over three consecutive cardiac cycles in patients with sinus rhythm, and over five cardiac cycles for those with atrial fibrillation. In the presence of atrial fibrillation, care was taken to obtain measurements during less irregular heart rate, trying to match temporally similar beats and thus preventing unrepresentative results. To evaluate the presence and severity of aortic regurgitation (AR) after TAVI, a combination of the qualitative and semi-quantitative parameters was used according to current guidelines. 14 We assessed intra-prosthetic AR with a method similar to that used for the evaluation of native valve regurgitation. Briefly, we used the ratio of the regurgitant jet to the LV outflow tract width and defined AR as follows: <25% mild, 26-64% moderate, and >65% severe. Because paravalvular regurgitant jets are often irregular with an eccentric contour and non-cylindrical 'spray', the parasternal short-axis view(s) was weighted more heavily than other signals for providing an integrated assessment of paravalvular regurgitation (PVR). PVR was rated as follows: none, no regurgitant colour flow; trace, pinpoint jet in AV; mild, jet arc length < _10% of the annulus circumference; moderate, jet arc length 10-30% of the annulus circumference; severe, jet arc length > _30% of the annulus circumference.
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Criteria of prosthetic structural valve deterioration
An echocardiographic diagnosis of SVD was made using the following pre-defined parameters: cusp thickness > _3 mm, presence of calcification and abnormal cusp motion. 13 All these parameters were referred to changes intrinsic to the valve. To better define SVD vs. other potential prosthetic abnormalities (i.e. prosthesis endocarditis or thrombosis), thickening or calcifications of valve cusps had to involve the leaflet free margin. The final study sample was divided into two groups according to this morphological criteria. Moreover, in each group according to the recommendations of the Valve Academic Research Consortium-2 (VARC-2), evaluation of valve function and morphology was performed using the patient's own initial post-implant study as a reference for serial comparisons. 16 The pre-discharge echocardiography evaluates initial valve appearance (position and circularity of the stent, and leaflet morphology and motion) and gives a comprehensive haemodynamic assessment using an integrative approach based on multiple parameters. Therefore, mild prosthesis stenosis was defined as: AVA 0. , peak velocity > _4 m/s, and mean trans-aortic pressure gradient > _40 mmHg. 16 The valve function was assessed over time both in patients with and without SVD considering the pre-discharge exam. All echocardiographic examinations were performed by two physicians (M.M., G.T.) with more than 10 years of echocardiographic experience. Evaluation of SVD was made by the same two clinicians who were blinded to each other in the assessment of prosthetic valve morphology. Discrepancies between the two observers were resolved by reanalysis and consensus to obtain a final agreement on the interpretation of echocardiographic findings.
Statistical analysis
Continuous data are presented as mean ± SD and categorical variables as frequencies (percentages), as appropriate. Differences between patients with and without SVD were assessed with unpaired Student's t test for continuous variables, and with v 2 test or Fisher's exact test (if the expected cell count was <5) for categorical variables, as appropriate. Oneway ANOVA for repeated measures was used to analyse the repeated continuous data and post hoc analysis for significant results were performed using the Bonferroni correction. Two-way ANOVA for repeated measures was used to analyse differences over time between patients with and without SVD. Several clinical and echocardiographic characteristics were tested in a univariate logistic regression analysis in order to evaluate whether some characteristics before the procedure and at discharge could help in predicting the occurrence of SVD at long-term follow-up. Variables with a P < 0.10 at univariate analysis were then included in a multivariate logistic regression analysis with enter method for the identification of independent variables predicting SVD. All results were considered significant with P values <0.05. Statistical analysis was performed using SPSS 23 (SPSS Inc, Chicago, IL).
Results
Study population
Between April 2008 and December 2011, 318 patients underwent successful TAVI. Mortality rate and the number of echocardiographic exams available at 1-year and 5-year follow-up are shown in Figure 1 and Table 1 . At 5-year, 148 patients (47%) died and cardiovascular death occurred in 67 patients (21%) at 5-year follow-up. Causes of cardiovascular death were: congestive heart failure (35 cases out of 67, 52%), acute coronary syndrome (15 cases, 22%), aortic dissection (5 cases, 8%), unknown (11 cases, 16%), endocarditis (1 cases, 2%). A total of 96 patients had an echocardiogram performed at long-term follow-up (56% of patients at risk). The mean echocardiographic follow-up was 4.9 ± 0.9 years (range 44-95 months, median 4.8 years), and the mean clinical follow-up was 5.4 ± 1.0 years (range 44-95 months, median 5.2 years). SVD were not observed in any patient at 1-year follow-up, whereas 29 (30%) patients showed SVD at 5-year follow-up.
Baseline characteristics
Baseline clinical and procedural characteristics of the study population are summarized in Table 2 . Patients with SVD were more likely to be female with a smaller body surface area compared to patients without SVD. All other baseline clinical variables were similar in the two groups. TAVI was performed through the transfemoral approach in 80.2% of patients, with no statistically significant difference in the rate of transfemoral route according to SVD. Patients with SVD were treated more frequently with smaller valves. There was no difference in the valve type implanted between patients with and without SVD. The majority of patients were discharged with antiplatelet therapy and the occurrence of SVD at 5-year follow-up was not associated with the use of different antithrombotic regimens (vitamin K antagonist and/ or antiplatelet therapy). There were no significant differences in the baseline echocardiographic characteristics of the study population stratified according to SVD at 5-year follow-up ( Table 3) .
Echocardiographic findings at 5-year follow-up
The echocardiographic parameters before discharge, at 1-year and 5-year follow-up after TAVI are summarized in meeting criteria for SVD, a significant reduction in AVA together with an increase in mean and peak aortic pressure gradients were observed at the latest echocardiographic evaluation (Figure 2 ). Mild prosthesis stenosis was found in seven patients, while one patient only reached the criteria for severe prosthesis stenosis. Moreover, the rate of central AR > _2 was higher in patients with SVD compared to those without SVD at the latest follow-up, while no significant difference was found regarding PVR > _2 in both groups. Figures 3 and 4 show the structural and functional changes over time in a patient with SVD and in one without SVD, respectively. At univariate analysis, the variables independently associated with SVD at 5-year follow-up were female sex, low body surface area, use of a 23-mm transcatheter valve and a small AVA at pre-discharge echocardiogram. However, at multivariate analysis only a small AVA was an independent predictor of SVD ( Table 5) . As regards the clinical status at 5-year follow-up, a slight increase of the number of patients in NYHA functional class III/IV was observed in patients with SVD (one patient at 1-year follow-up, five patients at the latest follow-up) compared to patients without SVD (zero patient at 1-year follow-up, one patient at latest follow-up).
Discussion
The main findings of our echocardiographic study concerning 5-year evaluation of patients who underwent TAVI with a balloonexpandable device are the following: (i) at 5-year follow-up, 30% of patients showed initial SVD and functional changes; (ii) female sex, low body surface area, use of a 23-mm transcatheter valve and small AVA at pre-discharge echocardiogram correlated with SVD, while only a small AVA was an independent predictor of SVD at multivariate analysis; (iii) in patients with SVD, no reintervention was needed and death was uncommon; (iv) haemodynamic consequences of SVD included a mild to moderate increase of the mean aortic gradient that did not reach the criteria for severe stenosis in most of the patients; (v) development of AR was a common (45%) finding in case of SVD, while PVR was not affected by SVD.
TAVI was initially performed only in patients at highest risk and its use has been gradually extended to intermediate and lower-risk patients. The long-term durability of transcatheter valves is therefore a crucial issue, especially if TAVI is to be considered for use in lower risk and younger patients. In this regard, few studies only have been performed assessing long-term outcome 11, 17, 18 and detailed structural and functional data are scarce. In the PARTNER trial, no SVD requiring surgical aortic valve replacement was detected after 5 years and the valve area as well as the mean transvalvular gradient remained stable.
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Another study reported that after 5 years, 9.7% of living patients showed moderate prosthesis failure without the need of reintervention. 9 Of note, no valve deterioration was detected at 4-year follow-up in the same cohort. Similarly, other reports have shown only moderate prosthesis dysfunction without need for reintervention. 10 Indeed, these studies were aimed at clinical follow-up and the majority showed no need for reintervention due to severe valve degeneration or failure. However, increase of prosthesis gradient over time was found in the majority of follow-up studies. Recently, a multicentre study demonstrated a mild but significant increase of transvalvular gradients over time after TAVI that was associated with the lack of anticoagulation therapy, a valve-in-valve procedure, a greater body mass index and the use of a 23-mm valve. 18 In our study, we investigated the 5-year echocardiography follow-up of SVD and their haemodynamic impact on valve function. Our study focused on echocardiographic and Doppler signs of initial SVD including cusp thickness > _3 mm, presence of calcification and abnormal cusp motion. These morphological data may better describe durability and progression of degeneration after TAVI. Twenty-nine (30%) patients had SVD at 5-year follow-up. At 1-year follow-up, SVD was not found in our series. Interestingly, despite patients with SVD showed an increase of transvalvular gradient, in the majority of cases this did not meet the criteria for severe stenosis in terms of either mean aortic gradient or valve area. Indeed, at the latest follow-up, AVA was 1.21 ± 0.27 cm 2 and mean aortic gradient 21 ± 7 mmHg. In parallel, central AR (but not PVR) was found in 45% of patients with SVD.
Comparison between the rate of SVD in our TAVI population and in surgical prosthetic aortic valves
In general, degeneration of valve bioprostheses encompasses a wide range of valve abnormalities such as calcification, leaflet tear, stent creep, and suture line disruption of bioprosthetic components. 4 The predominant mechanism of bioprosthetic valve dysfunction is structural deterioration. 19 Current data on the durability of surgical aortic bioprostheses show a non-linear trend with an inflection point occurring beyond 6 years after valve replacement. 5 Most studies analysing the factors influencing structural valve degeneration do not take the mode of valve failure into account and conclude that patient age at index surgery, site of implantation and valve type affect its occurrence.
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Concerning our study, we evaluated a balloon-expandable transcatheter valve with two sizes (23 and 26 mm) implanted in elderly patients (octogenarians) between April 2008 and December 2011. Similar to previous surgical data, we found that SVD correlated with the smaller size of the valve (23-mm) and a small AVA at predischarge echocardiogram. Of note, at multivariate analysis only a small AVA before discharge was an independent predictor of SVD. This is in agreement with previous surgical studies showing that a label valve size < _21 mm, effective orifice area, absence of anticalcification treatment and prosthetic valve mismatch were independent predictors of valve degeneration. 22, 23 Impaired renal function has been associated with degeneration of surgical biological valves. 5 In our population, we also found a higher rate of impaired renal function in patients with SVD that did not reach statistically significance. Of note, in the majority of surgical studies SVD at follow-up was defined based on severe haemodynamic deterioration requiring reoperation. Our echocardiography study on the Edwards Sapien transcatheter valve allows a reliable assessment of the SVD occurring in the valve leaflets over time. Our findings suggest that the rate of SVD (30%) at 5-year follow-up is slightly higher to that reported for surgically implanted bioprostheses where the occurrence of SVD is variable depending on the type of prosthesis. 3, 19, 21, 24, 25 However, despite the occurrence of SVD, severe stenosis and/or regurgitation were uncommon findings and no reintervention was needed within the follow-up period. Therefore, SVD defined according to our echocardiographic criteria were not associated with severe haemodynamic consequences.
Five-year haemodynamic consequences of SVD in our series
In a recent study, Del Trigo et al. 18 showed that increase of mean gradient is not a uniform process occurring in all patients who ). These data indicate that even in cases with SVD only a mild-to-moderate valve stenosis occurred. Small AVA at discharge was an independent predictor of SVD and this confirms the correlation between the final size of the implanted valve, defined not only by the nominal size (23 mm) but also and more importantly by the functional effective orifice area, and the risk of developing SVD.
Moreover, we found an increase in central AR > _2 in almost half of the patients with SVD probably because of fibro-calcification of the prosthetic tissue leading to leaflet retraction. Of note, central AR may influence aortic flow further increasing aortic mean gradient. In patients with SVD, the structural and functional alterations were not associated with changes in LV ejection fraction, LV volumes and pulmonary artery systolic pressure. This reinforces the concept that SVD in our series did not cause severe haemodynamic impairment in most of the cases and may explain why five patients only of the SVD group showed a significant worsening of NYHA functional class. However, clinical decline in these elderly patients should be looked in its proper perspective considering the impact of age increase during long-term follow-up. Interestingly, we did not observed an increase of PVR in patients with or without SVD throughout the follow-up suggesting that SVD did not influence PVR over time. Several studies 15, 26 clearly confirmed that patients with PVR have worse survival both immediately after TAVI and at 6 months. While central AR may be well explained by cusps thickening and/or retraction, typically observed in SVD, PVR is mainly due to incomplete annular sealing of the transcatheter valve within a calcified aortic valve, a phenomenon that has been recognized since the first TAVI series as an immediate post-implantation complication that generally does not increase over time.
Limitations of the study
There are some limitations of this study that should be acknowledged. First, we evaluated a relatively small number of patients given that some of the surviving patients were lost to follow-up and they did not perform an echocardiographic exam in our institution. However, the sample size was suitable to perform a comprehensive statistical analysis. Second, there was not an independent echocardiography core lab. Third, the study population represents the initial experience of our centre with TAVI and patients were treated with the first and second generation of the Edwards Sapien balloonexpandable valve. Thus, our data may not represent the results of more recent models of TAVI. Finally, we did not perform cardiac computed tomography that may potentially confirm SVD or diagnose prosthetic valve thrombosis.
